Cargando…

Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects

Buprenorphine is mainly metabolized by the cytochrome P450 (CYP) 3A4 enzyme. The aim of this study was to evaluate the role of first‐pass metabolism in the interaction of rifampicin and analgesic doses of buprenorphine. A four‐session paired cross‐over study design was used. Twelve subjects ingested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagelberg, Nora M., Fihlman, Mari, Hemmilä, Tuija, Backman, Janne T., Laitila, Jouko, Neuvonen, Pertti J., Laine, Kari, Olkkola, Klaus T., I. Saari, Teijo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226287/ https://www.ncbi.nlm.nih.gov/pubmed/28097004 http://dx.doi.org/10.1002/prp2.271

Ejemplares similares

Feasibility of a transmucosal sublingual fentanyl tablet as a procedural pain treatment in colonoscopy patients: a prospective placebo-controlled randomized study
por: Fihlman, Mari, et al.
Publicado: (2020)

Semimechanistic Population Pharmacokinetic Model to Predict the Drug–Drug Interaction Between S‐ketamine and Ticlopidine in Healthy Human Volunteers
por: Ashraf, Muhammad W., et al.
Publicado: (2018)

Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction
por: Tapaninen, Tuija, et al.
Publicado: (2019)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel
por: Itkonen, Matti K., et al.
Publicado: (2018)

Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers
por: Lohela, Terhi J., et al.
Publicado: (2020)

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France
por: Mezaache, Salim, et al.
Publicado: (2021)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Sublingual Buprenorphine: A Feasible Alternative for Treating Breakthrough Chronic Pain
por: Nair, Abhijit S, et al.
Publicado: (2019)

Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film
por: Gunderson, Erik W., et al.
Publicado: (2016)

Correction to: Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France
por: Mezaache, Salim, et al.
Publicado: (2021)

Effectiveness of Sublingual Buprenorphine and Fentanyl Pump in Controlling Pain After Open Cholecystectomy
por: Norozi, Vadood, et al.
Publicado: (2021)

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine
por: Komatsu, Ryu, et al.
Publicado: (2022)

Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2021)

Post-operative Analgesia in Opioid Dependent Patients: Comparison of Intravenous Morphine and Sublingual Buprenorphine
por: Alizadeh, Shaabanali, et al.
Publicado: (2015)

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
por: Martin, Yvette N., et al.
Publicado: (2019)

2198: Gender differences in the pharmacology of buprenorphine sublingual tablets in Hispanics/Latinos: An underrepresented population
por: Ivelisse Santiago, Darlene, et al.
Publicado: (2018)

Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
por: Kaski, Shane, et al.
Publicado: (2021)

Fulminant hepatic failure after intravenous injection of sublingual buprenorphine in a patient with hepatitis C
por: French, Janine, et al.
Publicado: (2015)

Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers
por: Fischer, Andreas, et al.
Publicado: (2015)

Comparison of sublingual buprenorphine and intravenous morphine in reducing bone metastases associated pain in cancer patients
por: Jamalian, Seyed Mohammad, et al.
Publicado: (2019)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Sublingual buprenorphine for acute renal colic pain management: a double-blind, randomized controlled trial
por: Payandemehr, Pooya, et al.
Publicado: (2014)

Sublingual Buprenorphine Efficacy in Renal Colic Pain Relief: A Randomized Placebo-Controlled Clinical Trial
por: Mozafari, Javad, et al.
Publicado: (2017)

Sublingual Buprenorphine and Methadone Maintenance Treatment: A Three-Year Follow-Up of Quality of Life Assessment
por: Giacomuzzi, Salvatore M., et al.
Publicado: (2005)

The effect of preoperative sublingual buprenorphine on postoperative pain after lumbar discectomy: A randomized controlled trial
por: Kiabi, Farshad Hassanzadeh, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
por: Björnsson, Marcus, et al.
Publicado: (2023)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico
por: Santiago, Darlene, et al.
Publicado: (2020)

Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report
por: Gracy*, Dr BK, et al.
Publicado: (2022)

A randomized controlled study to compare analgesic efficacy of sublingual buprenorphine and intravenous tramadol in patients undergoing mastectomy
por: Dokku, Krishna Sumanth, et al.
Publicado: (2022)

Intolerance of sublingual buprenorphine-naloxone during induction in a patient with end-stage liver disease: A case report
por: Behan, Jennifer, et al.
Publicado: (2016)

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2017)

Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021)

Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established needs to be continued and expanded
por: Kumar, M Suresh, et al.
Publicado: (2009)

Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study
por: Uusalo, Panu, et al.
Publicado: (2019)

Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study
por: Puustinen, Juha, et al.
Publicado: (2018)

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
por: Marsden, John, et al.
Publicado: (2022)

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation
por: Lowry, Natalie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t8nv9popam4usj5gpf7d6phne0